EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity

Rossana Di Staso, Beatrice Casadei, Marianna Gentilini, Serafina Guadagnuolo, Cinzia Pellegrini, Alessandro Broccoli, Davide Gori, Riccardo Masetti, Vittorio Stefoni, Francesca Bonifazi, Pier Luigi Zinzani, Lisa Argnani

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05766-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Rossana Di Staso und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell lymphoma who underwent leukapheresis between August 2019 and August 2022. All costs and medical resource consumption accountability were calculated on an intention-to-treat (ITT) basis, starting from leukapheresis to the time when the patient (infused or not) exited the CAR T-cell pathway for any reason. Eighty patients were addressed to leukapheresis and 59 were finally infused. After excluding CAR-T product cost, the main driver of higher costs were hospitalizations followed by the examinations/procedures and other drugs, respectively 43.9%, 26.3% and 25.4% of the total. Regarding costs of drugs and medications other than CAR T products, the most expensive items are those referred to AEs, both infective and extra-infective within 30 days from infusion, that account for 63% of the total. Density plot of cost analyses did not show any statistically significant difference with respect to the years of leukapheresis or infusion. To achieve finally 59/80 infused patients the per capita patients without CAR-T products results 74,000 euros. This analysis covers a growing concern on health systems, the burden of expenses related to CAR T-cell therapy, which appears to provide significant clinical benefit despite its high cost, thus making economic evaluations highly relevant. The relevance of this study should be also viewed in light of continuously evolving indications for this therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveAntigens, CD19Lymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedRetrospective StudiesAgedItalyAdultReceptors, Chimeric AntigenLeukapheresis

Stichwörter der Autor:innen

CAR T-cell pathwayEconomic evaluationIntention-to treatLarge B-cell lymphomasReal-life

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento Di Scienze Biomediche E Neuromotorie (DIBINEM), Università Di Bologna, Bologna, Italy.
  • Pediatric Oncology and Hematology, IRCCS Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy.
  • IRCCS Azienda-ospedaliero Universitaria Di Bologna, Bologna, Italy.
  • Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy. lisa.argnani@unibo.it.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Di Staso, R., Casadei, B., Gentilini, M., Guadagnuolo, S., Pellegrini, C., Broccoli, A., Gori, D., Masetti, R., Stefoni, V., Bonifazi, F., Zinzani, P. L., & Argnani, L. (2024). Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity. Annals of Hematology. https://doi.org/10.1007/s00277-024-05766-0

Vancouver

Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, et al. Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity. Annals of Hematology. 2024. doi:10.1007/s00277-024-05766-0

BibTeX
@article{DiStaso2024,
  author = {Di Staso, Rossana and Casadei, Beatrice and Gentilini, Marianna and Guadagnuolo, Serafina and Pellegrini, Cinzia and Broccoli, Alessandro and Gori, Davide and Masetti, Riccardo and Stefoni, Vittorio and Bonifazi, Francesca and Zinzani, Pier Luigi and Argnani, Lisa},
  title = {Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05766-0}
}
Kostenlos starten →